FDA Approves Tests from Siemens, Becton Dickinson, and Roche in FebruaryMarch 15th, 2018
Roche Diagnostics Named One of the 2018 “Top 70 Companies for Executive Women”March 14th, 2018
AACC Annual Scientific Meeting and Clinical Lab Expo
ChicagoBooth No.: 3849
Medlab - The World’s Largest Expo
DubaiBooth No.: Z5 G 42
MEDICA 2017 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
69th AACC Annual Meeting and Clinical Lab Expo - July 30 - August 3, 2017
SAN DIEGO, CA, USA
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
Lipoprotein (a) [Lp(a)] Test Kit (liquid stable), R1: 1 x 60 ml R2: 1 x 20 ml
Diazyme’s Lp(a) is a dual liquid stable reagent system which provides reliable results and is offered with time saving instrument specific packaging options which eliminate reagent transfer and increase operator efficiency. Instrument specific packaging options including Roche Hitachi 917 series, Olympus AU (400/600/640/680), Beckman Synchron CX, LX and DXC. The method requires only 6 ml of serum sample completed in less than 10 minutes and has excellent correlation with existing commercial products with r2 of 0.998, slope of 0.989, and y intercept of 0.0279. The assay has intra precision values of less than 5%. Not all Lp(a) methods correlate well with IFCC standards. The antibodies used in the Diazyme Lp(a) assay method show virtually no Lp(a) size effects producing consistent reliable results. The reagent is stable for 16 months from date of manufacture when stored @ 2°- 8°C.
The Diazyme Lp(a) is intended as a latex particle enhanced immunoturbidimetric assay for the in vitro quantitative determination of lipoprotein(a) [Lp(a)] concentration in human serum or plasma (EDTA) on Clinical Chemistry Systems. The measurement of Lp(a) is useful in evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular diseases in specific populations, when used in conjunction with clinical evaluation. For in vitro diagnostic use only.